| scholarly article | Q13442814 |
| P50 | author | Gerald I. Shulman | Q52509909 |
| Ralph A. DeFronzo | Q58689309 | ||
| P2093 | author name string | W Zawalich | |
| L Rossetti | |||
| P2860 | cites work | Decreased Sensitivity of the Pancreatic Beta Cells to Glucose in Prediabetic and Diabetic Subjects: A Glucose Dose-Response Study | Q69166799 |
| Role of glucose in arginine-induced insulin release in man | Q69935845 | ||
| Blood-brain glucose transfer: repression in chronic hyperglycemia | Q70185240 | ||
| Differential Sensitivity to β-Cell Secretagogues in “Early,” Type I Diabetes Mellitus | Q70354239 | ||
| A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties | Q70469025 | ||
| Insulin response to glucose, tolbutamide, secretin, and isoprenaline in maturity-onset diabetes mellitus | Q70498836 | ||
| Stimulation of counterregulatory hormonal responses in diabetic man by a fall in glucose concentration | Q72125645 | ||
| Early Phase of Insulin Release | Q72127794 | ||
| Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 | ||
| Glucose clamp technique: a method for quantifying insulin secretion and resistance | Q34191986 | ||
| Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas | Q34467786 | ||
| The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor | Q34502378 | ||
| Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions | Q34527799 | ||
| Modulation of proinsulin messenger RNA after partial pancreatectomy in rats. Relationships to glucose homeostasis | Q34631236 | ||
| Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release | Q36989349 | ||
| Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus | Q37004187 | ||
| Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes Mellitus | Q40078988 | ||
| Mechanism of glucose-induced insulin secretion | Q40120434 | ||
| New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus | Q40144631 | ||
| Insulin secretion in diabetes mellitus | Q40302183 | ||
| Glucose modulation of amino acid-induced glucagon and insulin release in the isolated perfused rat pancreas | Q40368566 | ||
| The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus | Q40992063 | ||
| Adaptation of B and A cell function during prolonged glucose infusion in human subjects | Q41565048 | ||
| The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia | Q41618288 | ||
| Diet-Induced Improvement of Abnormalities in Insulin and Glucagon Secretion and in Insulin Receptor Binding in Diabetes Mellitus* | Q41630573 | ||
| Abnormalities of insulin responses after ambient and previous exposure to glucose in streptozocin-diabetic and dexamethasone-treated rats. Role of hyperglycemia and increased B-cell demands | Q42044548 | ||
| Glucose Insensitivity and Amino-acid Hypersensitivity of Insulin Release in Rats with Non-insulin-dependent Diabetes: A Study with the Perfused Pancreas | Q42454625 | ||
| Platelet-density analysis and intraplatelet granule content in young insulin-dependent diabetics | Q43936381 | ||
| Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus | Q47205801 | ||
| The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. | Q51639006 | ||
| Subtotal pancreatectomy in five different rat strains: incidence and course of development of diabetes. | Q51642152 | ||
| Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal | Q51642223 | ||
| The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. | Q51643012 | ||
| Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. | Q51660630 | ||
| Beta-cell function improved by supplementing basal insulin secretion in mild diabetes | Q51670942 | ||
| Abnormal Insulin Secretion in a Streptozocin Model of Diabetes: Effects of Insulin Treatment | Q60192501 | ||
| Abnormal Glucose Regulation of Insulin Secretion in Models of Reduced B-Cell Mass | Q60192530 | ||
| Islet Secretion in a New Experimental Model for Non-insulin-dependent Diabetes | Q60192625 | ||
| The pancreatic islets in diabetes | Q67262870 | ||
| Inhibition of insulin secretion by exogenous insulin in normal man as demonstrated by C-peptide assay | Q67326840 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperglycemia | Q271993 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1037-1044 | |
| P577 | publication date | 1987-10-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats | |
| P478 | volume | 80 |
| Q35643225 | A higher-carbohydrate, lower-fat diet reduces fasting glucose concentration and improves β-cell function in individuals with impaired fasting glucose |
| Q53438315 | A ketogenic diet impairs energy and glucose homeostasis by the attenuation of hypothalamic leptin signaling and hepatic insulin signaling in a rat model of non-obese type 2 diabetes. |
| Q34684209 | A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes |
| Q46854245 | A preliminary fast may potentiate response to a subsequent low-salt, low-fat vegan diet in the management of hypertension - fasting as a strategy for breaking metabolic vicious cycles |
| Q28585782 | Animal Model for Maturity-onset Diabetes of the Young Generated by Disruption of the Mouse Glucokinase Gene |
| Q36732130 | Anti-Diabetic Activities of Gastrodia elata Blume Water Extracts Are Mediated Mainly by Potentiating Glucose-Stimulated Insulin Secretion and Increasing β-Cell Mass in Non-Obese Type 2 Diabetic Animals |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q43993113 | Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. |
| Q34422778 | Beta-cell deterioration--prospects for reversal or prevention |
| Q44686996 | Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study |
| Q68063409 | Beta-cell dysfunction in hyperglycaemic rat models: recovery of glucose-induced insulin secretion with lowering of the ambient glucose level |
| Q71458211 | Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse |
| Q37692849 | Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes |
| Q54347651 | Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. |
| Q34114554 | Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. |
| Q38074337 | Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae |
| Q51366919 | Chronic stress and carbohydrate metabolism: persistent changes and slow return to normalcy in male albino rats. |
| Q38515085 | Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor |
| Q38014516 | Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings |
| Q40511503 | Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle |
| Q24234557 | Dapagliflozin for type 2 diabetes mellitus |
| Q35578244 | Dapagliflozin lowers plasma glucose concentration and improves β-cell function |
| Q40846007 | Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. |
| Q35214420 | Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes |
| Q63384107 | Development of SGLT1 and SGLT2 inhibitors |
| Q46958824 | Diabetes in children and adolescents. Areas of controversy |
| Q35080402 | Dietary macronutrient composition affects β cell responsiveness but not insulin sensitivity |
| Q28743462 | Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance |
| Q38085691 | Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus |
| Q91891093 | Dissecting the Brain/Islet Axis in Metabesity |
| Q35696511 | Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance |
| Q34227891 | Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes |
| Q35691425 | Early diabetic neuropathy: triggers and mechanisms |
| Q51276351 | Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. |
| Q28732080 | Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models |
| Q89332880 | Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics |
| Q54194095 | Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. |
| Q34219847 | Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors |
| Q38005020 | Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus |
| Q39816362 | Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects |
| Q50000790 | Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM. |
| Q38638523 | Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus |
| Q54322866 | Evidence for a primary role of insulin resistance in the pathogenesis of type 2 diabetes. |
| Q90178371 | Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas |
| Q73650157 | Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications |
| Q33952149 | Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. |
| Q36690218 | First approved inhaled insulin therapy for diabetes mellitus |
| Q40553849 | Genetic epidemiology of non-insulin-dependent diabetes. |
| Q73790765 | Glucoregulation after canine islet transplantation: contribution of insulin secretory capacity, insulin action, and the entero-insular axis |
| Q51569886 | Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus. |
| Q42770564 | Glucose transporter-1 in the hypothalamic glial cells mediates glucose sensing to regulate glucose production in vivo |
| Q34425147 | High glucose predisposes gene expression and ERK phosphorylation to apoptosis and impaired glucose-stimulated insulin secretion via the cytoskeleton |
| Q39777493 | Huang-Lian-Jie-Du-Tang supplemented with Schisandra chinensis Baill. and Polygonatum odoratum Druce improved glucose tolerance by potentiating insulinotropic actions in islets in 90% pancreatectomized diabetic rats |
| Q42478438 | Hyperresponse in calcium-induced insulin release from electrically permeabilized pancreatic islets of diabetics GK rats and its defective augmentation by glucose |
| Q38765909 | Hypothalamic Insulin Resistance in Obesity: Effects on Glucose Homeostasis |
| Q43863063 | Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects |
| Q51569892 | Impact of family history of diabetes on the assessment of beta-cell function. |
| Q51373546 | Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. |
| Q42481072 | Impaired insulin action but normal insulin receptor activity in diabetic rat liver: effect of vanadate |
| Q33932757 | Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide |
| Q41653857 | In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: possible relevance to the maladaptive responses to chronic hyperglycaemia |
| Q54358800 | In vivo insulin resistance in streptozotocin-diabetic rats--evidence for reversal following oral vanadate treatment. |
| Q36407215 | Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus |
| Q51563266 | Influence of streptozotocin-induced diabetes in rats on the lithium content of tissue and the effect of dietary lithium supplements on this diabetic condition. |
| Q37846528 | Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus |
| Q34733637 | Insulin resistance in type 1 diabetes |
| Q54105933 | Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. |
| Q77909717 | Insulin secretion and biosynthesis by the perfused pancreas of spontaneously hypertensive rats |
| Q42434876 | Insulin secretion and glucose tolerance after islet transplantation in rats with noninsulin-dependent diabetes induced by neonatal streptozotocin |
| Q39532297 | Insulin treatment of non-insulin-dependent diabetes mellitus |
| Q54194092 | Insulin-mediated and glucose-mediated glucose uptake following hemipancreatectomy in healthy human donors. |
| Q34197036 | Intra-islet insulin permits glucose to directly suppress pancreatic A cell function |
| Q46084783 | Islet beta cell failure in the 60% pancreatectomised obese hyperlipidaemic Zucker fatty rat: severe dysfunction with altered glycerolipid metabolism without steatosis or a falling beta cell mass |
| Q34698810 | Islet beta cell failure in type 2 diabetes |
| Q39854329 | Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials |
| Q34228824 | Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. |
| Q37813419 | Liraglutide in the management of type 2 diabetes |
| Q46520896 | Long-term consumption of saponins derived from Platycodi radix (22 years old) enhances hepatic insulin sensitivity and glucose-stimulated insulin secretion in 90 % pancreatectomized diabetic rats fed a high-fat diet |
| Q38201162 | Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport |
| Q42327470 | Mechanism for leptin's acute insulin-independent effect to reverse diabetic ketoacidosis |
| Q38305698 | Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence |
| Q46896184 | Molecular disruption of hypothalamic nutrient sensing induces obesity |
| Q43228766 | Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them |
| Q57160966 | Optimal Insulin Treatment in Syngeneic Islet Transplantation |
| Q45820834 | Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors |
| Q34223186 | Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus |
| Q41756772 | Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. |
| Q51763308 | Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. |
| Q36633317 | Phlorizin Supplementation Attenuates Obesity, Inflammation, and Hyperglycemia in Diet-Induced Obese Mice Fed a High-Fat Diet |
| Q54243455 | Phlorizin treatment of diabetic rats partially reverses the abnormal expression of genes involved in hepatic glucose metabolism. |
| Q35995949 | Phlorizin: a review |
| Q34139048 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment |
| Q47993316 | Polyphenolic compounds from Malus hupehensis and their free radical scavenging effects |
| Q35604634 | Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations |
| Q42455250 | Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. |
| Q38076486 | Putting medications where they belong: practical advice for managing type 2 diabetes in clinical practice |
| Q33451134 | Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients |
| Q36345951 | Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus |
| Q39035951 | Renal, metabolic and cardiovascular considerations of SGLT2 inhibition |
| Q44189200 | Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes |
| Q37650996 | Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies |
| Q41095098 | Role of insulin resistance in the pathogenesis of NIDDM. |
| Q39578344 | Role of insulin resistance in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus |
| Q42153763 | SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function |
| Q38734956 | SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns |
| Q36745809 | SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models |
| Q47096334 | Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro |
| Q37468412 | Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus |
| Q64294550 | Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control |
| Q38821464 | Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician |
| Q92988627 | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II |
| Q85111372 | Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism‐Based Model Characterizing Sodium‐Glucose Cotransporter‐2 Inhibition |
| Q36175431 | Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus |
| Q38614488 | The effect of SGLT2 inhibitors on cardiovascular events and renal function. |
| Q30311821 | The effect of pancreatic polypeptide on glucose disposal after surgical alterations of the pancreas |
| Q30365939 | The entero-insular axis: implications for human metabolism. |
| Q35757207 | The medial amygdalar nucleus: a novel glucose-sensing region that modulates the counterregulatory response to hypoglycemia |
| Q42873604 | The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats |
| Q33705046 | The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance |
| Q37632127 | The renal effects of SGLT2 inhibitors and a mini-review of the literature |
| Q37940036 | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. |
| Q37505529 | Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis |
| Q46678833 | To: Godsland IF, Jeffs JA, Johnston DG (2004) loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157-1166. |
| Q54256321 | Treatment of diabetes mellitus. |
| Q40696805 | Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review |
| Q37750278 | Type 2 diabetes: an expanded view of pathophysiology and therapy |
| Q34198692 | Update on developments with SGLT2 inhibitors in the management of type 2 diabetes |
| Q91970207 | What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition |
| Q33354192 | Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? |
Search more.